Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aaron Koonce

Neurology Columbia, MO Doctor of Osteopathy

NPI 1902844384 CMS profile 502934

402 N Keene St, Columbia, MO 65201

Open in the dashboard

General payments

$5,199

311 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Koonce of Columbia, MO is reported in the CMS Open Payments database as having received $5,199 across 311 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82 4
2024 General $14 1
2023 General $608 35
2022 General $861 52
2021 General $1,247 75
2020 General $1,015 62
2019 General $1,372 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Koonce
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Aaron Koonce were reported at $82. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Aaron Koonce Neurology median Middle half National median
2019 $1,372 $474 $118–$2,177 $163
2020 $1,015 $367 $82–$2,309 $114
2021 $1,247 $438 $104–$2,547 $132
2022 $861 $442 $103–$2,388 $149
2023 $608 $464 $119–$2,312 $160
2024 $14 $468 $119–$2,323 $164
2025 $82 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $745 45 payments
  2. EMD Serono, Inc. $402 24 payments
  3. UCB, Inc. $335 21 payments
  4. Allergan Inc. $325 23 payments
  5. Alexion Pharmaceuticals, Inc. $259 13 payments
  6. Amgen Inc. $236 13 payments
  7. Biohaven Pharmaceuticals, Inc. $231 13 payments
  8. Lilly USA, LLC $227 11 payments
  9. Biogen, Inc. $198 10 payments
  10. Lundbeck LLC $183 11 payments
  11. Other $2,058 127 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,144 307 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56 4 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $370 22 payments
  2. DUOPA $357 21 payments
  3. AIMOVIG $218 13 payments
  4. Briviact $216 13 payments
  5. Soliris $207 10 payments
  6. UBRELVY Neuroscience $179 11 payments
  7. BOTOX $163 15 payments
  8. UBRELVY Neuroscience $151 8 payments
  9. QULIPTA $134 8 payments
  10. Mavenclad $121 8 payments
  11. Other $2,861 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

719

Median for Neurology: 833

Drug cost

$16,466

Median for Neurology: $202,670

Branded share of claims

11.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Generic 110 $4,052
Pyridostigmine Bromide Generic 36 $3,284
Donepezil Hcl Generic 223 $1,746
Levetiracetam Generic 35 $941
Primidone Generic 25 $922
Gabapentin Generic 27 $805
Carbidopa-Levodopa Carbidopa/Levodopa Brand 34 $685
Divalproex Sodium Er Divalproex Sodium Brand 17 $670
Oxcarbazepine Generic 15 $635
Rizatriptan Rizatriptan Benzoate Brand 17 $554

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$40,504

Medicare's payments for the services billed

Medicare patients

305

Average age 73

Services billed

832

162 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 53%
Depression 34%
Alzheimer's or dementia 31%
Diabetes 28%
Chronic kidney disease 22%
Ischemic heart disease 21%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

311 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record